Rhythm Pharmaceuticals Inc.公布了截至2024年1月1日的最新季度业绩,引发了公司股价在当日盘中大涨6.55%。
财报显示,Rhythm Pharmaceuticals Inc.本季度营收同比增长47.8%至3325万美元,高于分析师的平均预期。公司调整后每股亏损73美分,虽然较上年同期略有改善,但也优于分析师预测的每股亏损80美分。
分析人士指出,Rhythm Pharmaceuticals Inc.本季度业绩表现超出市场预期,主要得益于较高的营收增长以及亏损幅度较预期收窄。这反映了公司在业务拓展和成本管控方面的积极努力,提振了投资者对公司发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.